THE GC PLAYBOOK
Strategic Intelligence for Pharma & Biotech Legal Leaders
DEEP DIVE | April 2026
Hikma v. Amarin: Four Things Every Pharma GC Should Be Doing Right Now
Before the Supreme Court Rules
By John LaRocca | Former CLO, Actavis · Eagle Pharmaceuticals · Aerie Pharmaceuticals · Y-mAbs Therapeutics
The Supreme Court will hear oral argument in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. on April 29, 2026. The case will determine whether a generic company that fully carved out a patented indication from its label can still face induced infringement liability based on its press releases, website content, and marketing communications — conduct the Federal Circuit found sufficient to state a plausible inducement claim even though the skinny label itself did not reference the patented use.
Most of the commentary to date has focused on what the Court might decide. That analysis matters, but it misses the more urgent question: What should in-house counsel be doing now, while the case is pending?
The answer is: quite a lot. The Federal Circuit’s 2024 decision reversing the District of Delaware’s dismissal of Amarin’s claims is the operative law today. It will remain the operative law until the Supreme Court rules — and a decision is not expected until late June or early July 2026 at the earliest. That creates a window of exposure that both generic-side and brand-side GCs need to manage proactively.
Here are four workstreams that should already be underway.
1. Launch the Communications Audit Now
The core of the Federal Circuit’s reasoning was that inducement need not be established by the skinny label alone. The court held that Amarin’s complaint plausibly alleged inducement when the label was evaluated alongside Hikma’s non-label conduct — specifically, press releases describing the product as a “generic version of Vascepa,” website content categorizing the product under the broad therapeutic heading of “Hypertriglyceridemia,” and the citation of total Vascepa sales figures that reflected revenue driven overwhelmingly by the patented cardiovascular indication.
The practical implication is that every piece of external-facing communication about a skinny-label product is now potential evidence in an inducement case. That includes press releases at launch and afterward, investor presentations and earnings call transcripts, product website copy and therapeutic categorization, sales representative training materials and call scripts, formulary dossiers and payer communications, and social media and digital marketing content.
Generic-side GCs with active skinny-label products on the market should be commissioning a comprehensive communications audit immediately. The question to answer is straightforward: Does any company communication, taken together with the skinny label, plausibly suggest to a physician that this product can or should be used for a carved-out indication?
This is not a task to defer until the Supreme Court rules. The Federal Circuit standard is enforceable today. Companies with ongoing skinny-label launches are accumulating potential exposure with every press release and website update. The time to scrub the communications portfolio is now, while the audit can still remediate the risk rather than merely document it for litigation discovery.
Brand-side counsel should be conducting the mirror-image exercise: cataloging the generic competitor’s non-label communications to assess whether a viable inducement theory exists under the Federal Circuit’s framework. The strength of that evidence portfolio will directly affect both litigation positioning and licensing negotiation leverage.
2. Escalate to the Board
This is not a routine IP monitoring matter. The potential damages exposure warrants CLO-level escalation and, in many cases, board-level awareness.
The benchmark is the GSK v. Teva litigation over generic carvedilol (Coreg). In that case, a Delaware jury awarded GSK a $235 million verdict after finding that Teva’s skinny label, combined with its broader conduct, induced infringement of GSK’s method-of-use patent for congestive heart failure. The Federal Circuit reinstated that verdict in 2021 after a tortured procedural history, and the Supreme Court declined to review it in 2023. GSK and Teva ultimately settled in early 2026, but the $235 million figure — arrived at by a jury and sustained on appeal — remains the industry’s reference point for skinny-label damages exposure.
In Amarin’s case, the potential damages calculus is substantially larger. Vascepa’s cardiovascular risk-reduction indication, approved in December 2019, was the commercial engine of the franchise. Amarin projected peak sales in the “multiple billions” based on the CV indication. Analysts forecasted peak annual revenue as high as $3.2 billion. Even in its initial post-CV-approval year, Amarin guided for $650–700 million in total U.S. revenue, the vast majority attributable to the CV indication rather than the legacy severe hypertriglyceridemia use. Any damages model keyed to sales attributable to the patented CV indication — as inducement damages theories typically are — will generate exposure numbers that dwarf the Coreg verdict.
For generic companies selling skinny-label icosapent ethyl products — and there are multiple ANDA holders on the market — this exposure is direct and immediate. For other generic companies with skinny-label products in different therapeutic areas, the Hikma v. Amarin outcome will set the precedent that governs their own litigation risk. Either way, this belongs in the board risk committee’s field of vision.
Brand-side GCs should be framing the opportunity symmetrically. If the Supreme Court affirms or narrows the Federal Circuit’s approach, brand companies with multi-indication products will gain a powerful enforcement tool — but one that requires the evidentiary groundwork of documented generic communications to deploy. That enforcement strategy deserves board visibility and budget authorization.
3. Update the M&A Diligence Checklist
Every pharmaceutical M&A transaction involves intellectual property diligence. After Hikma v. Amarin, that diligence must expand to cover a category of risk that most deal teams have not historically examined with sufficient rigor: the communications conduct surrounding skinny-label products.
On the buy side — whether acquiring a generic platform or purchasing a branded asset with generic competition — the diligence protocol should now include specific inquiries into:
• Whether any target-company product uses or faces a skinny-label carve-out
• The complete inventory of press releases, website content, investor communications, and marketing materials referencing the product
• Any internal communications policies or protocols governing how the product is described externally
• Whether any brand company has asserted or threatened inducement claims
• Existing monitoring systems for tracking physician prescribing patterns relative to the labeled versus carved-out indications
• The adequacy of indemnification and insurance coverage for induced-infringement claims
The importance of this expanded diligence extends to both sides of the brand/generic divide. A company acquiring a generic platform with multiple skinny-label products is acquiring the full communications history of those products — and the litigation exposure embedded in that history. A company acquiring a branded asset with active generic competition will want to understand whether the generic competitors’ conduct supports enforcement action that could protect the acquired asset’s revenue base.
For PE-backed acquisitions — which now represent a significant share of specialty pharma deal flow — this analysis is particularly consequential. PE sponsors expect their portfolio companies to quantify litigation contingencies with precision. A newly acquired generic company with unaudited skinny-label communications represents a contingent liability that could materially affect the investment thesis.
4. Monitor the Antitrust Counterpunch
The patent and inducement issues have dominated the commentary, but there is a second legal front in the Hikma-Amarin dispute that brand-side GCs cannot afford to ignore.
In 2023, Hikma filed an antitrust lawsuit against Amarin, alleging that Amarin had deliberately locked up the supply of icosapent ethyl — Vascepa’s active pharmaceutical ingredient — through exclusive agreements with five API suppliers. Hikma’s complaint alleged that Amarin’s stated strategy was to protect Vascepa’s commercial potential “to beyond 2030 through a combination of patent protection, regulatory exclusivity, trade secrets and by taking advantage of manufacturing barriers to entry.” Teva filed a similar antitrust challenge in 2024, raising overlapping supply-exclusion allegations.
The antitrust claims are a reminder that the legal risk in skinny-label disputes runs in both directions. Brand companies that deploy aggressive lifecycle management strategies — particularly strategies that extend beyond patent enforcement into supply-chain control — face independent antitrust exposure. Exclusive API supply agreements designed to foreclose generic entry can constitute monopolistic conduct under Section 2 of the Sherman Act, regardless of whether the underlying patents are valid and enforceable.
For brand-side GCs, the practical takeaway is that antitrust compliance review must run in parallel with IP enforcement strategy. The fact that a company holds valid patents on a specific indication does not immunize its supply-chain arrangements from antitrust scrutiny. Any strategy that combines patent enforcement with API supply restrictions, manufacturing capacity lockups, or distribution exclusivity warrants a dedicated antitrust assessment — ideally before the strategy is implemented, not after a generic competitor files a complaint.
Generic-side GCs should treat Hikma’s antitrust theory as a template. If your company faces supply constraints that appear engineered by a brand competitor, the Hikma v. Amarin antitrust litigation provides a roadmap for a potential affirmative claim. That claim can serve as both an independent cause of action and a strategic counterweight in settlement negotiations.
THE OPERATIONAL TAKEAWAY
The Supreme Court’s decision in Hikma v. Amarin will be significant. It may clarify the pleading standard for induced infringement, define the evidentiary role of non-label communications, and potentially address the broader relationship between the Hatch-Waxman Section viii carve-out pathway and § 271(b) inducement liability. The Solicitor General, who supported the grant of certiorari and urged the Court to rule for Hikma, has been granted divided argument time — a signal that the government’s perspective will feature prominently in the Court’s analysis.
But waiting for the opinion is not a strategy. The Federal Circuit’s 2024 decision is generating real-world consequences today. Generic companies are accumulating communications that could support inducement claims. Brand companies are building enforcement dossiers. Transactions are closing without adequate skinny-label diligence. And supply-chain strategies are operating without parallel antitrust review.
The GCs who will be best positioned — regardless of which way the Court rules — are the ones who are acting now.
ABOUT THE AUTHOR
John LaRocca is the founder of the LaRocca Pharma Law Group and publisher of The GC Playbook. He has served as CLO and Deputy General Counsel at Actavis, and General Counsel at Eagle Pharmaceuticals, Aerie Pharmaceuticals, and Y-mAbs Therapeutics (through its acquisition by SERB Pharmaceuticals), bringing over 35 years of in-house pharmaceutical and biotech legal leadership to the newsletter’s analysis. Columbia Law School. Barred in New York and New Jersey.
The GC Playbook delivers weekly deal intelligence, regulatory analysis, and strategic legal commentary at the intersection of pharma M&A, PE-backed specialty pharma, and FDA regulatory strategy.
This article is provided for informational and educational purposes only and does not constitute legal advice. Readers should consult qualified legal counsel regarding specific situations.


